C
Carlos C. Campbell
Researcher at Centers for Disease Control and Prevention
Publications - 24
Citations - 1669
Carlos C. Campbell is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Plasmodium falciparum & Malaria. The author has an hindex of 17, co-authored 24 publications receiving 1646 citations.
Papers
More filters
Journal ArticleDOI
Genetic Selection of a Plasmodium-Refractory Strain of the Malaria Vector Anopheles gambiae
Frank H. Collins,Richard K. Sakai,Kenneth D. Vernick,Susan M. Paskewitz,Douglas C. Seeley,Louis H. Miller,William E. Collins,Carlos C. Campbell,Robert W. Gwadz +8 more
TL;DR: Production of fully refractory and fully susceptible mosquito strains was achieved through a short series of selective breeding steps, indicating a relatively simple genetic basis for refractoriness and encourages consideration of genetic manipulation of natural vector populations as a malaria control strategy.
Journal ArticleDOI
Beyond Chloroquine: Implications of Drug Resistance for Evaluating Malaria Therapy Efficacy and Treatment Policy in Africa
P B Bloland,Eve M. Lackritz,Peter N. Kazembe,J.B.O. Were,Richard W. Steketee,Carlos C. Campbell +5 more
TL;DR: Treatment with chloroquine can no longer be considered adequately effective therapy of clinical P. falciparum malaria in very young children in these areas of Africa.
Journal ArticleDOI
Severe Cutaneous Reactions among American Travelers Using Pyrimethamine-Sulfadoxine (Fansidar®) for Malaria Prophylaxis
Kirk D. Miller,Hans O. Lobel,Richard F. Satriale,Joel N. Kuritsky,Robert S. Stern,Carlos C. Campbell +5 more
TL;DR: In the United States it is now recommended that the routine weekly use of the fixed combination of pyrimethamine and sulfadoxine (PYR/SDX) be reserved for those travelers at highest risk of acquiring chloroquine-resistant P. falciparum, when alternate prophylactic regimens are not deemed appropriate.
Journal ArticleDOI
Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum.
William E. Collins,Robin F. Anders,Marguerite Pappaioanou,Gary H. Campbell,G. V. Brown,David J. Kemp,Ross L. Coppel,Jimmie C. Skinner,Patricia M. Andrysiak,J M Favaloro,Lynn M. Corcoran,J. Roger Broderson,Graham F. Mitchell,Carlos C. Campbell +13 more
TL;DR: An immunization trial using Aotus monkeys and Escherichia coli-derived fused polypeptides corresponding to various regions of the RESA molecule protected against overwhelming infection, and protection correlated with antibody responses to either of two different repetitive sequences in RESA.
Journal ArticleDOI
In vivo efficacy of chloroquine treatment for Plasmodium falciparum in Malawian children under five years of age.
TL;DR: Considering these therapeutic results and the higher cost and limited availability of alternative therapies, chloroquine 25 mg/kg therapy was adopted as the primary therapy for malaria in Malawi.